Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vivimed LabsNSE:VIVIMEDLAB -1.97%34 3-Year EBITDA Growth Rate is 7.20% as of Mar. 2026, which is 56% below its 10-year median of 16.20. GuruFocus rates NSE:VIVIMEDLAB with a GF Score™ of 34/100 and a GF Value™ of ₹2.45 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 813 Drug Manufacturers companies, Vivimed Labs ranks worse than 52.77% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 7.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Vivimed Labs was 82.60% per year. The lowest was -66.50% per year. And the median was 16.20% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Vivimed Labs 3-Year EBITDA Growth Rate Related Terms
NSE:VIVIMEDLAB vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vivimed Labs's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivimed Labs 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vivimed Labs's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Vivimed Labs's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 7.20% mean?
Vivimed Labs (NSE:VIVIMEDLAB) has a 3-Year EBITDA Growth Rate of 7.20% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Vivimed Labs and its competitors. This is 56% below median its historical median of 16.20. According to the industry distribution chart, Vivimed Labs ranks #429 out of 813 companies in the Drug Manufacturers industry, placing it in the top 52.8%.
Is Vivimed Labs' 3-Year EBITDA Growth Rate too high?
Vivimed Labs' current 3-Year EBITDA Growth Rate of 7.20% is 56% below median its 10-year median of 16.20. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.80. Vivimed Labs' value of 7.20% is 18.2% below this industry median. Based on the distribution chart, Vivimed Labs ranks #429 out of 813 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Vivimed Labs has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vivimed Labs' 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vivimed Labs ranks #429 out of 813 companies for 3-Year EBITDA Growth Rate. This places Vivimed Labs in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.80. Vivimed Labs' value of 7.20% is 18.2% below this benchmark. While the company's 10-year median is 16.20 vs. the industry median of 8.80, Vivimed Labs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.80, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vivimed Labs's current 3-Year EBITDA Growth Rate of 7.20% is 18.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Vivimed Labs and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivimed Labs's current 3-Year EBITDA Growth Rate is 7.20%, which is 56% below median its own 10-year median of 16.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivimed Labs stock overvalued right now?
Based on GuruFocus' analysis, Vivimed Labs (NSE:VIVIMEDLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹2.45, compared to a current price of ₹4.98 — trading 103.3% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 7.20%, which is 56% below median its 10-year median of 16.20 and 18.2% below the Drug Manufacturers industry median of 8.80. Vivimed Labs' overall GF Score™ is 34/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Vivimed Labs (NSE:VIVIMEDLAB), the current 3-Year EBITDA Growth Rate is 7.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vivimed Labs (NSE:VIVIMEDLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Vivimed Labs stock appears to be overvalued.
The current stock price of ₹4.98 is trading 103.3% above its estimated GF Value™ of ₹2.45.
GuruFocus considers Vivimed Labs to be Significantly Overvalued.
Key valuation signals for NSE:VIVIMEDLAB:
3-Year EBITDA Growth Rate: 7.20% (56% below median its 10-year median of 16.20)
GF Value™: ₹2.45 vs. price of ₹4.98 (103.3% above fair value)
Industry Position: 18.2% below the Drug Manufacturers median (#429 of 813)
No single metric tells the full story. See the NSE:VIVIMEDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vivimed Labs Ltd is an India-based company that is engaged in the Business of Active pharmaceutical ingredients, Intermediates, Nutraceutical ingredients, CDMO Finished Dosage Formulation, Specialty Chemicals, and Retail Branded Formulation manufacturing. The company has three reportable segments: the Speciality Chemicals Business, the Pharma Business, and others. The majority of revenue is earned through the Pharma business.
34GF Score
Get the complete analysis for NSE:VIVIMEDLAB
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VIVIMEDLAB has been successfully added to your 
